Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic, Wegovy and Rybelsus) may drastically reduce or even eliminate their need for injected insulin. Those are the remarkable findings of a small University at Buffalo study reported in the New England Journal of Medicine and published online on Sept. 6.